Item 5.07 Submission of Matters to a Vote of Security Holders

Core Laboratories N.V. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") on May 20, 2020 in Amsterdam, the Netherlands. At the Annual Meeting, the Company's shareholders were requested: (1) To elect two Class I Supervisory Directors ; (2) To appoint KPMG, including its U.S. and Dutch affiliates, (collectively, "KPMG") as the Company's independent registered public accountants for the year ending December 31, 2020 (3) To confirm and adopt our Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2019, following a discussion of our Dutch Report of the Management Board for that same period; (4) To approve and resolve the cancellation of our repurchased shares held at 12:01 a.m. CEST on May 20, 2020; (5) To approve and resolve the extension of the existing authority to repurchase up to 10% of our issued share capital from time to time for an 18-month period, until November 20, 2021, and such repurchased shares may be used for any legal purpose; (6) To approve and resolve the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to our common and preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021; (7) To approve and resolve the extension of the authority to limit or exclude the preemptive rights of the holders of our common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021; To: (8a) approve, on an advisory basis, the compensation of our executive officers as described in the Compensation Discussion and Analysis ("CD&A") section of the proxy statement filed by the Company on March 20, 2020; (8b) cast a favorable advisory vote on the remuneration report referred to in Section 2:135b of the Dutch Civil Code for the fiscal year ended December 31, 2019; (8c) adopt the remuneration policy for the Management Board and the Supervisory Board in line with new Dutch legal requirements; (9) To approve and resolve the amendment and restatement of the Core Laboratories N.V. 2014 Long-Term Incentive Plan (the "LTIP"), the principal purposes of which are to increase the number of shares authorized for issuance thereunder by 1.1 million shares and to extend the term of the LTIP through May 20, 2025.

Given that more than 50% of the issued share capital was present and represented at the meeting, item numbers 1 through 8(b) and item number 9 could be approved by the affirmative vote of a majority of votes cast. Item number 8(c) required an affirmative vote of 75% of the votes cast. All items were approved and the certified results of the matters voted upon at the Annual Meeting are as follows:

Proposal No. 1 - Election of Class I Directors: The election of the Class I supervisory director was approved as follows:




         Nominee                 For        Withheld    Broker Non-Votes

Harvey Klingensmith          32,348,638     150,577           4,728,264
Monique van Dijken Eeuwijk   32,341,062     158,153           4,728,264

Proposal No. 2 - Appointment of KPMG as Independent Registered Public Accountant: The appointment of KPMG as the independent registered public accountant for the year ending December 31, 2020 was approved as follows:

--------------------------------------------------------------------------------





   For       Against   Abstentions   Broker Non-Votes

37,094,396   106,524     26,559             -

Proposal No. 3 - Confirm and Adopt the Dutch Statutory Annual Accounts: The confirmation and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2019 was approved as follows:




   For       Against   Abstentions   Broker Non-Votes

37,120,816   74,895      31,768             -

Proposal No. 4 - Approve and Resolve the Cancellation of Repurchased Shares: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at 12:01 a.m. CEST on May 20, 2020 was approved as follows:




   For       Against   Abstentions   Broker Non-Votes

37,081,788   111,640     34,051             -

Proposal No. 5 - Approve Extension - Repurchase up to 10% of Issued Share Capital: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital from until November 20, 2021 was approved as follows:




   For       Against   Abstentions   Broker Non-Votes

36,512,522   662,734     52,223             -

Proposal No. 6 - Approve Extension to Issue Shares and/or Grant Rights: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021 was approved as follows:




   For       Against   Abstentions   Broker Non-Votes

36,895,931   286,176     45,372             -

Proposal No. 7 - Approve Extension to Limit or Exclude Preemptive Rights: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021 was approved as follows:




   For       Against   Abstentions   Broker Non-Votes

36,941,201   214,491     71,787             -

--------------------------------------------------------------------------------

Proposal No. 8a - Approve the Compensation of the Company's Executive Officers: The compensation program regarding the Company's named executive officers was approved, on an advisory basis, as follows:




   For        Against    Abstentions   Broker Non-Votes

                                          4,728,264


30,489,269   1,909,539     100,407

Proposal No. 8b - Cast a favorable advisory vote on the Remuneration Report for the Fiscal year ended December 31, 2019: The remuneration report was approved, on an advisory basis, as follows:




                                                                              Broker
   For                           Against                       Abstentions   Non-Votes

              1,903,502 Proposal No. 8b - Cast a favorable
              advisory vote on the Remuneration Report for
              the Fiscal year ended December 31, 2019: The
                 remuneration report was approved, on an
                       advisory basis, as follows:
             ForAgainstAbstentionsBroker
             Non-Votes35,702,4362,510,25132,7862,625,157
30,485,938                                                       109,775     4,728,264

Proposal No. 8c - Adopt the Remuneration Policy for the Management Board and the Supervisory Board in line with new Dutch legal requirements: The remuneration policy was approved, as follows:

For Against Abstentions Broker Non-Votes



30,895,503   1,560,974     42,738         4,728,264

Proposal No. 9 - Approve and Resolve the Amendment and Restatement of the Core Laboratories 2014 Long-Term Incentive Plan: The proposal regarding the LTIP was approved, as follows:




   For        Against    Abstentions   Broker Non-Votes

30,980,658   1,480,684     37,873         4,728,264

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses